Viagra Research Today is a free monthly online journal that collates and summarizes the latest research about Viagra, including details on sildenafil, erectile dysfunction, impotence, side-effects, alternatives.

Central serous chorioretinopathy associated with sildenafil.

Fraunfelder FW, Fraunfelder FT

Casey Eye Institute, Oregon Health & Science University, Portland, OR 97239-4197, USA. eyedrug@ohsu.edu

PURPOSE:: To investigate a suspected relationship between central serous chorioretinopathy (CSC) and sildenafil therapy. METHODS:: For this retrospective, observational case series, the authors reviewed over 1,500 case reports of sildenafil-associated ocular side effects from the postmarketing surveillance databases of the Food and Drug Administration (FDA), the World Health Organization (WHO), and the National Registry of Drug-Induced Ocular Side Effects. They also performed a Medline literature search for "retinopathy, retinal edema, macular edema" (terms associated with CSC) and "sildenafil." They identified 11 cases of CSC in men taking sildenafil. RESULTS:: In 8 of 11 cases, patients stopped sildenafil therapy when CSC occurred. In 6 of these 8 cases, patients' vision improved after sildenafil cessation. In 3 cases, effects recurred when patients resumed sildenafil therapy, but stopping therapy was not associated with improvement of CSC in every case. Two patients continued to experience CSC after sildenafil cessation. CONCLUSION:: Practitioners who see patients with refractory CSC should consider recommending cessation of sildenafil therapy; however, because of the cyclic nature of CSC, a causal relationship has not yet been established. Additional possible case reports can be sent to the National Registry of Drug-Induced Ocular Side Effects, the FDA, the WHO, or the manufacturer.

Published 9 April 2008 in Retina, 28(4): 606-9.
Full-text of this article is available online (may require subscription).

© 2004-2008 Viagra Research Today. All Rights Reserved.